Prognostic marker analysis in pediatric intracranial ependymomas
- 407 Downloads
Histologic grading methods dependent upon H&E staining review have not been shown to reliably predict survival in children with intracranial ependymomas due to the subjectivity of the analytical methods. We hypothesized that the immunohistochemical detection of MIB-1, Tenascin C, CD34, VEGF, and CA IX may represent objective markers of post-operative survival (Progression Free and Overall Survival; PFS, OS) in these patients. Intracranial ependymomas from patients aged 22 years or less were studied. The original histologic grade was recorded, H&E sections were reviewed for vascular proliferation status, and immunohistochemistry was used to determine MIB-1, Tenascin C, CD34, VEGF, and CA IX status. Based upon the World Health Organization (WHO) grading system, 3 Grade I, 18 Grade II and 9 Grade III ependymomas were studied. Median follow-up time was 9.0 years; median PFS was, 6.1 years. Original WHO grade did not correlate with PFS or OS. Peri-necrotic CA IX localization correlated with PFS (Log rank = 0.0181) and OS (Log rank p = 0.0015). All patients with a CA IX ≤ 5 % total area localization were alive at last follow-up. Perinecrotic CA IX staining was also associated with vascular proliferation (p = 0.006), though not with VEGF expression score. MIB-1 labeling index (LI) correlated with OS (HR 1.06, 95 % CI 1.01, 1.12) and PFS (HR 1.08, 95 % CI 1.02, 1.14). MIB-1 LI and perinecrotic CA IX individually correlated with PFS. The effect of perinecrotic CA IX remained when grade was added to a Cox model predicting PFS. Immunodetection of CA IX and MIB-1 expression are predictive biomarkers for survival in children with posterior fossa ependymomas. These markers represent objective indicators of survival that supplement H&E grading alone.
KeywordsPediatric Ependymoma Immunohistochemistry Vascular endothelial growth factor MIB-1 Carbonic anhydrase IX
The authors gratefully acknowledge funding from the Pediatric Brain Tumor Foundation (REM, DS, and ME salary support). The authors also appreciate the editorial support of Ms. Bonnie Lynch. The abstract was reported in part at the 20th International Congress of Brain Tumor Research and Therapy, Lake Tahoe, California. July 20–23, 2014.
Conflict of interest
The authors declare that they have no conflict of interest.
The research was performed under waiver of consent following review of the protocol by the Duke Institutional Review Board (# Pro00030787).
- 1.McLendon RE, Wiestler OD, Kros JM, Korshunov A, Ng H-K (2007) Ependymoma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) WHO classification of tumours of the central nervous system, 4th edn. IARC Press, Lyon, pp 72–74Google Scholar
- 3.Tihan T, Zhou T, Holmes E, Burger PC, Ozuysal S, Rushing EJ (2008) The prognostic value of histological grading of posterior fossa ependymomas in children: a Children’s Oncology Group study and a review of prognostic factors. Mod Pathol 21:165–177. doi: 10.1038/modpathol.3800999 PubMedGoogle Scholar
- 4.Raghunathan A, Wani K, Armstrong TS, Vera-Bolanos E, Fouladi M, Gilbertson R, Gajjar A, Goldman S, Lehman NL, Metellus P, Mikkelsen T, Necesito-Reyes MJ, Omuro A, Packer RJ, Partap S, Pollack IF, Prados MD, Robins HI, Soffietti R, Wu J, Miller CR, Gilbert, Aldape KD, Collaborative Ependymoma Research N (2013) Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system. Brain Pathol 23:584–594. doi: 10.1111/bpa.12050 CrossRefPubMedGoogle Scholar
- 6.Preusser M, Heinzl H, Gelpi E, Hoftberger R, Fischer I, Pipp I, Milenkovic I, Wohrer A, Popovici F, Wolfsberger S, Hainfellner JA (2008) Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Histopathology 53:39–47. doi: 10.1111/j.1365-2559.2008.03065.x CrossRefPubMedGoogle Scholar
- 7.Kurt E, Zheng PP, Hop WC, van der Weiden M, Bol M, van den Bent MJ, Avezaat CJ, Kros JM (2006) Identification of relevant prognostic histopathologic features in 69 intracranial ependymomas, excluding myxopapillary ependymomas and subependymomas. Cancer 106:388–395. doi: 10.1002/cncr.21608 CrossRefPubMedGoogle Scholar
- 9.Preusser M, Wolfsberger S, Haberler C, Breitschopf H, Czech T, Slavc I, Harris AL, Acker T, Budka H, Hainfellner JA (2005) Vascularization and expression of hypoxia-related tissue factors in intracranial ependymoma and their impact on patient survival. Acta Neuropathol 109:211–216. doi: 10.1007/s00401-004-0938-8 CrossRefPubMedGoogle Scholar
- 11.Gururangan S, Fangusaro J, Poussaint TY, Onar A, Gilbertson R, Packer R, McLendon R, Friedman H, Boyett J, Kun LL (2010) Lack of efficacy of bevacizumab + CPT-11 in children with recurrent ependymoma: a pediatric brain tumor consortium study. In: Pediatric brain tumor consortium spring meeting, 2011Google Scholar
- 12.Sathornsumetee S, Cao Y, Marcello JE, Herndon JE II, McLendon RE, Desjardins A, Friedman HS, Dewhirst MW, Vredenburgh JJ, Rich JN (2008) Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol 26:271–278. doi: 10.1200/JCO.2007.13.3652 CrossRefPubMedCentralPubMedGoogle Scholar
- 14.Birner P, Piribauer M, Fischer I, Gatterbauer B, Marosi C, Ambros PF, Ambros IM, Bredel M, Oberhuber G, Rossler K, Budka H, Harris AL, Hainfellner JA (2003) Vascular patterns in glioblastoma influence clinical outcome and associate with variable expression of angiogenic proteins: evidence for distinct angiogenic subtypes. Brain Pathol 13:133–143CrossRefPubMedGoogle Scholar
- 15.Ellison DW, Kocak M, Figarella-Branger D, Felice G, Catherine G, Pietsch T, Frappaz D, Massimino M, Grill J, Boyett JM, Grundy RG (2011) Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts. J Negat Results Biomed 10:7. doi: 10.1186/1477-5751-10-7 CrossRefPubMedCentralPubMedGoogle Scholar
- 16.CBTRUS (2008) Supplement report: primary brain tumors in the United States, 2004. In: Central brain tumor registry of the United States, Hinsdale, ILGoogle Scholar
- 17.Birner P, Gatterbauer B, Oberhuber G, Schindl M, Rossler K, Prodinger A, Budka H, Hainfellner JA (2001) Expression of hypoxia-inducible factor-1 alpha in oligodendrogliomas: its impact on prognosis and on neoangiogenesis. Cancer 92:165–171. doi: 10.1002/1097-0142(20010701)92:1<165 CrossRefPubMedGoogle Scholar
- 19.Bao B, Groves K, Zhang J, Handy E, Kennedy P, Cuneo G, Supuran CT, Yared W, Rajopadhye M, Peterson JD (2012) In vivo imaging and quantification of carbonic anhydrase IX expression as an endogenous biomarker of tumor hypoxia. PLoS One 7:e50860. doi: 10.1371/journal.pone.0050860 CrossRefPubMedCentralPubMedGoogle Scholar
- 22.Haapasalo JA, Nordfors KM, Hilvo M, Rantala IJ, Soini Y, Parkkila AK, Pastorekova S, Pastorek J, Parkkila SM, Haapasalo HK (2006) Expression of carbonic anhydrase IX in astrocytic tumors predicts poor prognosis. Clin Cancer Res 12:473–477. doi: 10.1158/1078-0432.CCR-05-0848 CrossRefPubMedGoogle Scholar